上皮细胞粘附分子
癌症研究
抗体
双特异性抗体
免疫疗法
化学
癌症免疫疗法
肿瘤微环境
T细胞
单克隆抗体
免疫学
免疫系统
生物
肿瘤细胞
作者
Gerhard Frey,Ana Paula G. Cugnetti,Haizhen Liu,Charles Xing,Christina E. Wheeler,Hwai Wen Chang,William J. Boyle,Jay M. Short
出处
期刊:mAbs
[Landes Bioscience]
日期:2024-03-06
卷期号:16 (1): 2322562-2322562
被引量:38
标识
DOI:10.1080/19420862.2024.2322562
摘要
Epithelial cell adhesion molecule (EpCAM) is a transmembrane glycoprotein that plays several roles in cancer biology. EpCAM is an attractive therapeutic target because of its expression in most solid tumors. However, targeting EpCAM has been challenging because it is also highly expressed in normal epithelial tissues. Initial attempts to develop EpCAM-specific T-cell engagers were unsuccessful due to severe cytokine release effects, as well as serious on-target, off-tumor drug-related toxicities. We developed novel, conditionally active biological (CAB) bispecific antibodies that bind to both EpCAM and CD3 in an acidic tumor microenvironment. In healthy tissues, binding to EpCAM and CD3 is greatly reduced by a novel, dual CAB selection, where each binding domain is independently blocked by the presence of physiological chemicals known as Protein-associated Chemical Switches (PaCS). The CAB anti-EpCAM T-cell engagers displayed the anticipated bispecific binding properties and mediated the potent lysis of EpCAM-positive cancer cell lines through the recruitment of T cells in the tumor microenvironment. Xenograft studies showed that the efficacy of CAB bispecific antibodies is similar to that of a non-CAB anti-EpCAM bispecific antibody, but they have markedly reduced toxicity in non-human primates, indicating an unprecedentedly widened therapeutic index of over 100-fold. These preclinical results indicate that the dual CAB bispecific antibody is potentially both a powerful and safe therapeutic platform and a promising T cell-engaging treatment for patients with EpCAM-expressing tumors.
科研通智能强力驱动
Strongly Powered by AbleSci AI